{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:05:18Z","timestamp":1789182318027,"version":"build-2803163510"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To investigate the impact of the M184V\/I mutation on virologic response to dolutegravir plus lamivudine (DTG + 3TC) in suppressed-switch populations, a meta-analysis was performed using virologic outcomes from people with human immunodeficiency virus type 1 (PWH) with and without M184V\/I before DTG + 3TC switch in real-world studies identified via systematic literature review. Sensitivity analyses were performed using data from PWH with M184V\/I in interventional studies identified via targeted literature review.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Single-arm meta-analyses using common- and random-effects models were used to estimate proportions of PWH with virologic failure (VF) among real-world populations with and without M184V\/I and interventional study participants with M184V\/I at 24, 48, and 96 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Literature reviews identified 5 real-world studies from 3907 publications and 51 abstracts meeting inclusion criteria and 5 interventional studies from 1789 publications and 3 abstracts. All time points had low VF incidence in PWH with M184V\/I (real-world: 1.43%\u20133.81%; interventional: 0.00%) and without (real-world: 0.73%\u20132.37%). Meta-analysis\u2013estimated proportions (95% confidence interval) with VF were low at weeks 24, 48, and 96, respectively, for PWH with M184V\/I (real-world: 0.01 [.00\u2013.04], 0.03 [.01\u2013.06], and 0.04 [.01\u2013.07]; interventional: 0.00 [.00\u2013.02], 0.00 [.00\u2013.01], and 0.00 [.00\u2013.03]) and without (real-world: 0.00 [.00\u2013.02], 0.02 [.01\u2013.04], and 0.02 [.00\u2013.05]). One real-world study (n = 712) reported treatment-emergent M184V at VF in 1 of 652 (0.15%) PWH without prior M184V\/I.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Results suggest that prior M184V\/I has minimal impact on virologic suppression after switching to DTG + 3TC and provide reassurance when considering switching regimens in virologically suppressed PWH with incomplete treatment history or limited treatment options.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad526","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T19:48:55Z","timestamp":1698436135000},"source":"Crossref","is-referenced-by-count":24,"title":["Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V\/I: A Systematic Literature Review and Meta-analysis"],"prefix":"10.1093","volume":"10","author":[{"given":"Madhusudan","family":"Kabra","sequence":"first","affiliation":[{"name":"ViiV Healthcare , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan J","family":"Barber","sequence":"additional","affiliation":[{"name":"Ian Charleson Day Centre, Royal Free London National Health Service Foundation Trust , London , United Kingdom"},{"name":"Institute for Global Health, University College London , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Allavena","sequence":"additional","affiliation":[{"name":"Department of Infectious and Tropical Diseases, Centre Hospitalier Universitaire H\u00f4tel-Dieu , Nantes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Inserm, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Assistance Publique\u2013H\u00f4pitaux de Paris, Laboratoire de Virologie, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[{"name":"Laboratory and Infectious Diseases Sciences, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico and Department of Safety and Bioethics, Universit\u00e0 Cattolica del Sacro Cuore , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Pasquau","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Virgen de las Nieves University Hospital , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Gianotti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M","family":"Llibre","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division and Fight Infections Foundation, Hospital Universitari Germans Trias i Pujol , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9951-712X","authenticated-orcid":false,"given":"David","family":"Rial-Crestelo","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre HIV Unit, , Madrid , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"De Miguel-Buckley","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas , Madrid , Spain"},{"name":"Hospital Universitario La Paz Infectious Diseases Unit, , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Blick","sequence":"additional","affiliation":[{"name":"Health Care Advocates International , Stratford, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Turner","sequence":"additional","affiliation":[{"name":"HEOR Ltd , Cardiff , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cale","family":"Harrison","sequence":"additional","affiliation":[{"name":"HEOR Ltd , Cardiff , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Wynne","sequence":"additional","affiliation":[{"name":"HEOR Ltd , Cardiff , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Verdier","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Montr\u00e9al, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M","family":"Parry","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn","family":"Jones","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinyere","family":"Okoli","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Donovan","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Priest","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Letang","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"2023112917435318300_ofad526-B1","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1128\/AAC.47.11.3377-3383.2003","article-title":"Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase","volume":"47","author":"Diallo","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2023112917435318300_ofad526-B2","article-title":"HIV drug resistance report 2021","author":"World Health Organization"},{"key":"2023112917435318300_ofad526-B3","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society\u2013USA panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"2023112917435318300_ofad526-B4","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s40121-022-00676-y","article-title":"HIV DNA sequencing to detect archived antiretroviral drug resistance","volume":"11","author":"Geretti","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2023112917435318300_ofad526-B5","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/infdis\/171.6.1411","article-title":"Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)","volume":"171","author":"Schuurman","year":"1995","journal-title":"J Infect Dis"},{"key":"2023112917435318300_ofad526-B6","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJM199512213332502","article-title":"Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter","volume":"333","author":"Eron","year":"1995","journal-title":"N Engl J Med"},{"key":"2023112917435318300_ofad526-B7","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1097\/QAD.0000000000001191","article-title":"The M184I\/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir","volume":"30","author":"Oliveira","year":"2016","journal-title":"AIDS"},{"key":"2023112917435318300_ofad526-B8","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with HIV-1: week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023112917435318300_ofad526-B9","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023112917435318300_ofad526-B10","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023112917435318300_ofad526-B11","author":"Underwood"},{"key":"2023112917435318300_ofad526-B12","author":"Scholten"},{"key":"2023112917435318300_ofad526-B13","author":"Hocqueloux"},{"key":"2023112917435318300_ofad526-B14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jgar.2022.07.022","article-title":"Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study","volume":"31","author":"Santoro","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2023112917435318300_ofad526-B15","author":"Santoro"},{"key":"2023112917435318300_ofad526-B16","doi-asserted-by":"crossref","first-page":"ofab103","DOI":"10.1093\/ofid\/ofab103","article-title":"Nucleoside reverse-transcriptase inhibitor resistance mutations predict virological failure in human immunodeficiency virus\u2013positive patients during lamivudine plus dolutegravir maintenance therapy in clinical practice","volume":"8","author":"Borghetti","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023112917435318300_ofad526-B17","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2019.09.002","article-title":"Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients","volume":"54","author":"Baldin","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023112917435318300_ofad526-B18","doi-asserted-by":"crossref","first-page":"105893","DOI":"10.1016\/j.ijantimicag.2020.105893","article-title":"Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients","volume":"55","author":"Galizzi","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2023112917435318300_ofad526-B19","doi-asserted-by":"crossref","first-page":"e16813","DOI":"10.1097\/MD.0000000000016813","article-title":"DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients","volume":"98","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2023112917435318300_ofad526-B20","author":"Reynes"},{"key":"2023112917435318300_ofad526-B21","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dkaa479","article-title":"Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: week 96 results of ART-PRO pilot study","volume":"76","author":"Rial-Crestelo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023112917435318300_ofad526-B22","author":"Blick"},{"key":"2023112917435318300_ofad526-B23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"2023112917435318300_ofad526-B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"2023112917435318300_ofad526-B25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.aids.0000218542.08845.b2","article-title":"Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)","volume":"20","author":"Castagna","year":"2006","journal-title":"AIDS"},{"key":"2023112917435318300_ofad526-B26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/infdis\/jiab413","article-title":"Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients","volume":"225","author":"Palich","year":"2022","journal-title":"J Infect Dis"},{"key":"2023112917435318300_ofad526-B27","doi-asserted-by":"crossref","DOI":"10.1177\/13596535221077487","article-title":"Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study","volume":"27","author":"Brown","year":"2022","journal-title":"Antivir Ther"},{"key":"2023112917435318300_ofad526-B28","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","article-title":"Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial","volume":"9","author":"Paton","year":"2022","journal-title":"Lancet HIV"},{"key":"2023112917435318300_ofad526-B29","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/QAD.0000000000003244","article-title":"High efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in people with suppressed HIV and preexisting M184V\/I","volume":"36","author":"Sax","year":"2022","journal-title":"AIDS"},{"key":"2023112917435318300_ofad526-B30","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jac\/dkaa019","article-title":"M184V\/I does not impact the efficacy of abacavir\/lamivudine\/dolutegravir use as switch therapy in virologically suppressed patients","volume":"75","author":"Jary","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023112917435318300_ofad526-B31","doi-asserted-by":"crossref","first-page":"ofz330","DOI":"10.1093\/ofid\/ofz330","article-title":"Impact of the M184V\/I mutation on the efficacy of abacavir\/lamivudine\/dolutegravir therapy in HIV treatment-experienced patients","volume":"6","author":"Olearo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2023112917435318300_ofad526-B32","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3018(17)30069-3","article-title":"Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286\/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial","volume":"4","author":"Ciaffi","year":"2017","journal-title":"Lancet HIV"},{"key":"2023112917435318300_ofad526-B33","doi-asserted-by":"crossref","first-page":"ofy113","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2023112917435318300_ofad526-B34","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12688\/f1000research.15995.1","article-title":"Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: systematic review and meta-analysis","volume":"7","author":"Wandeler","year":"2018","journal-title":"F1000Res"},{"key":"2023112917435318300_ofad526-B35","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/cid\/ciy1132","article-title":"Dolutegravir monotherapy versus dolutegravir\/abacavir\/lamivudine for virologically suppressed people living with chronic human immunodeficiency virus infection: the randomized noninferiority MONotherapy of TiviCAY trial","volume":"69","author":"Hocqueloux","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023112917435318300_ofad526-B36","author":"De Wit"},{"key":"2023112917435318300_ofad526-B37","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jrsm.1348","article-title":"Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions","volume":"10","author":"Schwarzer","year":"2019","journal-title":"Res Synth Methods"},{"key":"2023112917435318300_ofad526-B38","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"key":"2023112917435318300_ofad526-B39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"key":"2023112917435318300_ofad526-B40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","article-title":"The heterogeneity statistic I2 can be biased in small meta-analyses","volume":"15","author":"von Hippel","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"2023112917435318300_ofad526-B41","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/QAD.0000000000002850","article-title":"Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation","volume":"35","author":"Li","year":"2021","journal-title":"AIDS"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad526\/52635594\/ofad526.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/11\/ofad526\/53929095\/ofad526.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/11\/ofad526\/53929095\/ofad526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T17:44:38Z","timestamp":1701279878000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad526\/7331280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad526","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,10,27]]},"article-number":"ofad526"}}